Polyrizon (PLRZ) Competitors $1.06 -0.01 (-0.93%) As of 08:56 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PLRZ vs. RLYB, ALLR, NAII, CTXR, SONN, PASG, NNVC, GDTC, QTTB, and LSTAShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include Rallybio (RLYB), Allarity Therapeutics (ALLR), Natural Alternatives International (NAII), Citius Pharmaceuticals (CTXR), Sonnet BioTherapeutics (SONN), Passage Bio (PASG), NanoViricides (NNVC), CytoMed Therapeutics (GDTC), Q32 Bio (QTTB), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. Its Competitors Rallybio Allarity Therapeutics Natural Alternatives International Citius Pharmaceuticals Sonnet BioTherapeutics Passage Bio NanoViricides CytoMed Therapeutics Q32 Bio Lisata Therapeutics Polyrizon (NASDAQ:PLRZ) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Is PLRZ or RLYB more profitable? Polyrizon has a net margin of 0.00% compared to Rallybio's net margin of -5,473.33%. Polyrizon's return on equity of 0.00% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets PolyrizonN/A N/A N/A Rallybio -5,473.33%-71.66%-65.06% Do analysts rate PLRZ or RLYB? Rallybio has a consensus price target of $5.00, suggesting a potential upside of 734.72%. Given Rallybio's stronger consensus rating and higher probable upside, analysts plainly believe Rallybio is more favorable than Polyrizon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rallybio 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor PLRZ or RLYB? In the previous week, Rallybio had 3 more articles in the media than Polyrizon. MarketBeat recorded 4 mentions for Rallybio and 1 mentions for Polyrizon. Rallybio's average media sentiment score of 0.53 beat Polyrizon's score of 0.00 indicating that Rallybio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in PLRZ or RLYB? 90.3% of Rallybio shares are owned by institutional investors. 8.7% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, PLRZ or RLYB? Polyrizon has higher earnings, but lower revenue than Rallybio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyrizonN/AN/A-$1.54MN/AN/ARallybio$640K39.11-$57.78M-$0.94-0.64 SummaryRallybio beats Polyrizon on 7 of the 11 factors compared between the two stocks. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.35M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E RatioN/A20.8975.7726.43Price / SalesN/A458.96547.72119.09Price / CashN/A44.5237.0558.92Price / Book0.009.9311.346.06Net Income-$1.54M-$53.38M$3.29B$266.28M7 Day Performance-2.75%0.63%0.18%-0.33%1 Month Performance-8.62%6.31%6.30%3.43%1 Year PerformanceN/A11.63%57.50%23.10% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$1.06-0.9%N/AN/A$6.35MN/A0.00N/ANews CoverageRLYBRallybio3.282 of 5 stars$0.58-1.3%$5.00+759.1%-47.2%$24.32M$640K-0.6240Short Interest ↓Gap UpALLRAllarity Therapeutics2.5445 of 5 stars$1.60+0.6%$9.00+462.5%-65.3%$23.47MN/A0.0010Gap DownNAIINatural Alternatives InternationalN/A$3.77+5.3%N/A-43.4%$23.30M$113.80M-2.71290Positive NewsCTXRCitius Pharmaceuticals2.7663 of 5 stars$1.37-0.4%$53.00+3,782.8%-91.6%$23.22MN/A0.0020SONNSonnet BioTherapeutics2.0734 of 5 stars$3.42-3.7%$20.00+484.8%-59.7%$23.09M$20K0.0010Negative NewsShort Interest ↑PASGPassage Bio3.0778 of 5 stars$7.24+2.8%$91.75+1,167.3%-47.7%$23.02MN/A-0.40130NNVCNanoViricides0.8002 of 5 stars$1.42-0.4%N/A-21.0%$22.74MN/A-1.9720Short Interest ↓GDTCCytoMed Therapeutics2.0139 of 5 stars$2.04+1.2%$5.00+145.7%+27.5%$22.26M$69.50K0.00N/APositive NewsQTTBQ32 Bio3.0647 of 5 stars$1.79+4.1%$12.17+579.7%-96.0%$21.84M$1.16M-0.4239Positive NewsLSTALisata Therapeutics2.9422 of 5 stars$2.49-0.4%$23.50+843.8%-29.7%$21.81M$1M-1.1230Short Interest ↓Gap Down Related Companies and Tools Related Companies Rallybio Alternatives Allarity Therapeutics Alternatives Natural Alternatives International Alternatives Citius Pharmaceuticals Alternatives Sonnet BioTherapeutics Alternatives Passage Bio Alternatives NanoViricides Alternatives CytoMed Therapeutics Alternatives Q32 Bio Alternatives Lisata Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRZ) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
